Switch theme
Sign up to access all valuation multiples
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
2016
34
LTM Revenue $7.0M
Last FY EBITDA -$23.5M
-$31.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
LAVA Therapeutics has a last 12-month revenue (LTM) of $7.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, LAVA Therapeutics achieved revenue of $12.0M and an EBITDA of -$23.5M.
LAVA Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See LAVA Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.0M | XXX | $12.0M | XXX | XXX | XXX |
| Gross Profit | $7.0M | XXX | $12.0M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$23.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -196% | XXX | XXX | XXX |
| EBIT | -$31.7M | XXX | -$29.7M | XXX | XXX | XXX |
| EBIT Margin | -452% | XXX | -248% | XXX | XXX | XXX |
| Net Profit | -$27.9M | XXX | -$25.1M | XXX | XXX | XXX |
| Net Margin | -398% | XXX | -210% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, LAVA Therapeutics's stock price is $1.
LAVA Therapeutics has current market cap of $34.9M, and EV of -$31.4M.
See LAVA Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$31.4M | $34.9M | XXX | XXX | XXX | XXX | $-1.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, LAVA Therapeutics has market cap of $34.9M and EV of -$31.4M.
LAVA Therapeutics's trades at -2.6x EV/Revenue multiple, and 1.3x EV/EBITDA.
Equity research analysts estimate LAVA Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
LAVA Therapeutics has a P/E ratio of -1.2x.
See valuation multiples for LAVA Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $34.9M | XXX | $34.9M | XXX | XXX | XXX |
| EV (current) | -$31.4M | XXX | -$31.4M | XXX | XXX | XXX |
| EV/Revenue | -4.5x | XXX | -2.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBIT | 1.0x | XXX | 1.1x | XXX | XXX | XXX |
| EV/Gross Profit | -4.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.2x | XXX | -1.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLAVA Therapeutics's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $1.2M for the same period.
LAVA Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
LAVA Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for LAVA Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -196% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 237% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 348% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
LAVA Therapeutics acquired XXX companies to date.
Last acquisition by LAVA Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . LAVA Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was LAVA Therapeutics founded? | LAVA Therapeutics was founded in 2016. |
| Where is LAVA Therapeutics headquartered? | LAVA Therapeutics is headquartered in United States of America. |
| How many employees does LAVA Therapeutics have? | As of today, LAVA Therapeutics has 34 employees. |
| Who is the CEO of LAVA Therapeutics? | LAVA Therapeutics's CEO is Mr. Stephen A. Hurly. |
| Is LAVA Therapeutics publicy listed? | Yes, LAVA Therapeutics is a public company listed on NAS. |
| What is the stock symbol of LAVA Therapeutics? | LAVA Therapeutics trades under LVTX ticker. |
| When did LAVA Therapeutics go public? | LAVA Therapeutics went public in 2021. |
| Who are competitors of LAVA Therapeutics? | Similar companies to LAVA Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of LAVA Therapeutics? | LAVA Therapeutics's current market cap is $34.9M |
| What is the current revenue of LAVA Therapeutics? | LAVA Therapeutics's last 12 months revenue is $7.0M. |
| What is the current EV/Revenue multiple of LAVA Therapeutics? | Current revenue multiple of LAVA Therapeutics is -4.5x. |
| Is LAVA Therapeutics profitable? | Yes, LAVA Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
